MENLO PARK, Calif.--(BUSINESS WIRE)--March 27, 2006--Geron Corporation (Nasdaq:GERN) announced today that it has entered into two agreements with the University of Oxford relating to its program to produce dendritic cells from human embryonic stem cells (hESCs). In a license agreement with Isis Innovation Ltd., the University’s technology transfer company, Geron receives a worldwide exclusive license under patent applications filed by the University for pioneering work by Oxford scientists who derived dendritic cells from hESCs. In a linked research agreement, Geron will fund work in the University’s Sir William Dunn School of Pathology to further develop the technology under the guidance of Dr. Paul Fairchild and Professor Herman Waldmann.
